Angiogénese
Os inibidores da angiogênese são compostos que interferem na formação de novos vasos sanguíneos, um processo crítico no crescimento e metástase do câncer. Ao inibir a angiogênese, esses compostos podem restringir o suprimento de sangue para os tumores, retardando ou interrompendo seu crescimento. Os inibidores da angiogênese são essenciais na pesquisa do câncer e no desenvolvimento terapêutico, fornecendo insights sobre os mecanismos de progressão tumoral e oferecendo potenciais tratamentos para o câncer e outras doenças relacionadas à angiogênese. Na CymitQuimica, oferecemos uma ampla gama de inibidores da angiogênese de alta qualidade para apoiar sua pesquisa em oncologia e biologia vascular.
Subcategorias de "Angiogénese"
- BTK(159 produtos)
- Bcr-Abl(115 produtos)
- EGFR(594 produtos)
- FAK(72 produtos)
- FLT(90 produtos)
- Receptor do Factor de Crescimento Fibroblasto (FGFR)(182 produtos)
- JAK(246 produtos)
- PDGFR(126 produtos)
- RAAS(90 produtos)
- Src(81 produtos)
- Syk(37 produtos)
- Trombina(53 produtos)
- VDA(2 produtos)
- VEGFR(249 produtos)
Exibir 6 mais subcategorias
Foram encontrados 2092 produtos de "Angiogénese"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
MM-589
CAS:MM-589 is a potent WD repeat domain 5 (WDR5) inhibitor and mixed lineage leukemia (MLL) protein-protein interaction.Fórmula:C28H44N8O5Pureza:98%Cor e Forma:SolidPeso molecular:572.70Sacibertinib
CAS:Sacibertinib inhibits Trk, targeting EGFR-TK (EC50 110 nM) & HER2 (EC50 244 nM), with anticancer properties.Fórmula:C32H31ClN6O4Cor e Forma:SolidPeso molecular:599.08Lucitanib dihydrochloride
CAS:Lucitanib dihydrochloride (E-3810 dihydrochloride) is an efficient VEGFR1-3, FGFR1-3, and PDGFRalpha/β inhibitor, used in metastatic breast cancer research.Fórmula:C26H27Cl2N3O4Cor e Forma:SolidPeso molecular:516.42FGFR-IN-6
CAS:FGFR-IN-6 (Compound 5) is an FGFR inhibitor.Fórmula:C23H22N6O3Cor e Forma:SolidPeso molecular:430.46EGFR-IN-34
EGFR-IN-34 is a low-toxicity, acrylamide derivative antitumor agent that is a potent inhibitor of EGFR.Fórmula:C26H27ClN6O2Cor e Forma:SolidPeso molecular:490.98JAK-IN-19
JAK-IN-19 inhibits JAK (pIC50: 7.2, 7.7), less so for VEGFR2 (7.0) and Aurora B (5.8).Fórmula:C26H36FN5O2Cor e Forma:SolidPeso molecular:469.59HER2-IN-6
CAS:HER2-IN-6, a potent HER2 inhibitor, may target wild/mutant EGFR and HER2-mediated tumors. (Patent WO2021164697A1, compound 11)Fórmula:C26H32N8O3Cor e Forma:SolidPeso molecular:504.58GLPG3312
CAS:GLPG3312 is a selective and potent pan-SIK inhibitor with the advantage of oral activity, for SIK1, SIK2 and SIK3, anti-inflammatory and immunomodulatory .Fórmula:C23H21F2N5O3Pureza:98.53%Cor e Forma:SolidPeso molecular:453.44FGFR4-IN-10
FGFR4-IN-10 (compound 5a) is a potent, selective FGFR4 inhibitor with IC50 of 70.7 nM, sparing FGFR1-3.Fórmula:C20H19F3N6O3Cor e Forma:SolidPeso molecular:448.4FAK-IN-2
FAK-IN-2: potent oral FAK inhibitor, IC50 35 nM, reduces tumor growth, migration, and induces cell death.Fórmula:C28H31ClN8O3Cor e Forma:SolidPeso molecular:563.05EGFR/HER2-IN-5
EGFR/HER2-IN-5: Irreversible, oral dual EGFR inhibitor, IC50 0.6 nM, targets L858R/T790M mutations, anti-tumor in vivo for lung cancer study.Cor e Forma:SolidVEGFR-2-IN-10
VEGFR-2-IN-10 has enhanced antiangiogenic potency against VEGFR2 phosphorylation induced by VEGF with an IC50 value of 0.7 μM and no cytotoxic effects.Fórmula:C20H21N3O2Cor e Forma:SolidPeso molecular:335.4ALK-IN-31
CAS:ALK-IN-31 (Compound Ld-10) is an orally active ALK inhibitor with an IC50 of 1135 nM. It demonstrates excellent antiproliferative activity against lung cancer cells H2228, with an IC50 value of 1.35 μM. ALK-IN-31 induces apoptosis and arrests cell proliferation at the G0/G1 phase by affecting mitochondrial function. It exhibits antitumor effects by downregulating the expression of p-AKT and p-mTOR in the PI3K-AKT-mTOR signaling pathway downstream of ALK. This compound is applicable for research into non-small cell lung cancer (NSCLC).Fórmula:C30H33N5O2SCor e Forma:SolidPeso molecular:527.68EGFR-IN-24
EGFR-IN-24 is a potent inhibitor of EGFR and inhibits EGFR (del19/T790M/C797S) and EGFR (L858R/T790M/C797S).Fórmula:C30H35FN6O3Cor e Forma:SolidPeso molecular:546.64CDD-1115
CAS:<p>CDD-1115 is a potent and selective BMPR2 inhibitor, with an IC50 of 1.8 nM and a Kiapp of 6.2 nM. It effectively suppresses gene expression mediated by bone morphogenetic proteins (BMPs). BMPs regulate cellular processes in various tissue types, such as the kidneys, skeletal muscle, heart, and reproductive organs, and can induce ectopic bone formation.</p>Fórmula:C32H30N6O3Cor e Forma:SolidPeso molecular:546.619BTK-IN-7
BTK-IN-7 is a potent inhibitor for BTK with 4.0 nM IC50, highly selective over ITK and EGFR, showing strong antitumor activity.Fórmula:C30H32N6O4Cor e Forma:SolidPeso molecular:540.61EGFR/HER2-IN-6
EGFR/HER2-IN-6 is a dual inhibitor of EGFR, HER2, and DHFR with IC50s: 0.122, 0.078, and 0.585 μM, showing anticancer potential and selectivity.Fórmula:C18H21N5O3SCor e Forma:SolidPeso molecular:387.46FGFR4-IN-6
FGFR4-IN-6: covalent, reversible FGFR4 blocker, 5.4 nM IC50, good oral bioavailability, reduces Hep3B2.1-7 tumors in mice, low toxicity.Fórmula:C31H33N7O4Cor e Forma:SolidPeso molecular:567.64FGFR4-IN-9
FGFR4-IN-9 is a selective inhibitor of FGFR4 (IC50: 75.3 nM) that effectively inhibits the growth and angiogenesis of hepatocellular carcinoma cells.Fórmula:C24H22ClF3N4O4Cor e Forma:SolidPeso molecular:522.9EGFR-IN-17
EGFR-IN-17: potent, selective EGFR inhibitor, IC50 of 0.2 nM, overcomes C797S drug resistance.Fórmula:C27H31ClN7O3PCor e Forma:SolidPeso molecular:568.01
